ProCE Banner Activity

CheckMate 77T: Phase III Trial of Neoadjuvant Nivolumab + Chemotherapy vs Placebo + Chemotherapy With Adjuvant Nivolumab or Placebo in Stage II-IIIB NSCLC

Conference Coverage

In this randomized phase III trial, the addition of nivolumab to neoadjuvant chemotherapy and administered as adjuvant therapy was associated with a significant EFS benefit over neoadjuvant chemotherapy alone in patients with stage II-IIIB NSCLC.

Released: October 26, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc